Clene Inc.

CLNN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-26.2M $-39.4M $-49.5M $-29.9M $-9.7M $-19.3M $-16.2M
Depreciation & Amortization
Depreciation $1.5M $1.6M $1.7M $1.0M $955.0K $963.0K $848.0K
Amortization
Stock-Based Compensation $6.4M $8.0M $9.1M $8.5M $12.4M $761.0K $399.0K
Net Cash from Operating Activities $-18.5M $-21.3M $-30.2M $-39.0M $-34.6M $-18.9M $-13.2M
Investing Activities
Capital Expenditures $39.0K $15.0K $330.0K $5.2M $1.3M $387.0K $294.0K
Business Acquisitions
Net Cash from Investing Activities $-39.0K $6.3M $-1.5M $-10.2M $-1.3M $-387.0K $-294.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $11.5M $-1.5M $42.2M $17.2M $27.1M $69.5M $5.5M
Net Change in Cash $-7.0M $-16.7M $10.5M $-32.0M $-8.9M $50.5M $-8.0M
Free Cash Flow $-18.6M $-21.3M $-30.5M $-44.2M $-36.0M $-19.3M $-13.5M